A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.

导出 OA

翻译打印收藏纠错

作者： Dae Hyun,Yoo ^[1] ; Chang-Hee,Suh ^[2] ; Seung Cheol,Shim ^[3] ; Slawomir,Jeka ^[4] ; Francisco Fidencio,Cons-Molina ^[5] ; Pawel,Hrycaj ^[6] ; Piotr,Wiland ^[7] ; Eun Young,Lee ^[8] ; Francisco G,Medina-Rodriguez ^[9] ; Pavel,Shesternya ^[10] ; Sebastiao,Radominski ^[11] ; Marina,Stanislav ^[12] ; Volodymyr,Kovalenko ^[13] ; Dong Hyuk,Sheen ^[14] ; Leysan,Myasoutova ^[15] ; Mie Jin,Lim ^[16] ; Jung-Yoon,Choe ^[17] ; Sang Joon,Lee ^[18] ; Sung Young,Lee ^[18] ; Taek Sang,Kwon ^[18] ; Won,Park ^[16]

作者单位： Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea. ^[1] Ajou University Hospital, Suwon, Korea. ^[2] Chungnam National University Hospital, Daejeon, Korea. ^[3] University Hospital No. 2, Collegium Medicum in Bydgoszcz, UMK in Toruń, Poland. ^[4] Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico. ^[5] Poznań University of Medical Sciences, Poznań, Poland. ^[6] Medical University of Wrocław, Wrocław, Poland. ^[7] Seoul National University College of Medicine, Seoul, Korea. ^[8] LaSalle University, Philadelphia, Pennsylvania, USA. ^[9] Krasnoyarsk State Medical University, Krasnoyarsk, Russia. ^[10] Universidade Federal do Parana, Curitiba, Brazil. ^[11] Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia. ^[12] National Scientific Center, Kiev, Ukraine. ^[13] Eulji University Hospital, Daejeon, Korea. ^[14] Research Medical Complex Vashe Zdorovie, Kazan, Russia. ^[15] IN-HA University, School of Medicine, Incheon, Korea. ^[16] Catholic University of Daegu, School of Medicine, Daegu, Korea. ^[17] CELLTRION, Incheon, Korea. ^[18]

关键词 B cells DMARDs (biologic)Pharmacokinetics Rheumatoid Arthritis Treatment